Despite an overall decline in the numbers of people suffering from tuberculosis (TB), the disease remains a major public health challenge in the European region, reveals latest ECDC-WHO report Tuberculosis surveillance and monitoring in Europe 2019 (2017 data). An estimated 77,000 people are suffering from difficult-to-treat multidrug-resistant TB (MDR-TB) out of the 275,000 people newly diagnosed and with relapses of TB.
The European Union and European Economic Area (EU/EEA) countries fare better, with only 1 041 people reported to have MDR-TB. However, most countries in the Region, including many in the EU/EEA, struggle to treat patients successfully.
Drug-Resistant Tuberculosis
Drug-resistant tuberculosis (TB) is a globally serious infectious disease caused by the bacterium Mycobacterium tuberculosis. It occurs as multidrug-resistant or MDR TB or in its more severe form, extensively drug-resistant or XDR TB.
Advertisement
‘Early and rapid diagnosis of TB is integral to effectively treat the disease and to ease further suffering and transmission.’
Tweet it Now
Dr Vytenis Andriukaitis, European Commissioner for Health and Food Safety, said: "Even though tuberculosis is an ancient, preventable and curable disease, it still causes too much suffering and death to many people in the European Union and beyond. TB was high on the global agenda in 2018 and world leaders committed to mobilize efforts towards ending it. This momentum must be used to tackle tuberculosis from all angles and at all levels. The Commission has pledged its commitment to support the EU Member States towards reaching the goal of ending TB by 2030 as part of the wider Sustainable Development Agenda. Even though we are on the right track, sustained efforts centered on people are paramount to achieve a tuberculosis-free Europe and the world."
ECDC Director Dr Andrea Ammon believes in the capacity of the EU/EEA to improve: "We can end TB by 2030. However, as the burden in the region varies greatly, we will need to tailor approaches on a country-by-country basis. ECDC will continue to offer tailored country support and coordinate efforts across borders."
![Extra Pulmonary Tuberculosis]( "Extra Pulmonary Tuberculosis")
Extra pulmonary tuberculosis is infection of tissues and organs other than the lungs by mycobacterium tuberculosis and related organisms.
"TB is preventable and curable; the time to take action is now to end TB by 2030. If we don't act rapidly and decisively, the drug-resistant forms of the disease will increase their hold on Europe. Despite the challenges and threats that we face, I believe that Europe has the full potential to lead the way. We have science and technology, skilled health professionals and high level political commitment to leaving no-one behind - we have got what it takes to end TB", said Dr Zsuzsanna Jakab, WHO Regional Director for Europe.
The recent United Nations High-Level Meeting on TB, held in September 2018, brought hope to the world as global leaders stepped up their commitment to end TB by 2030, in line with the Sustainable Development Goals (SDGs). This political commitment now needs to be translated into action to end TB.
New hope for treatment of drug-resistant TB
Up until now, an MDR-TB diagnosis spelled the start of a grueling two-year treatment plan for patients. New WHO recommendations for the treatment of MDR-TB involve safer and more effective drugs with reduced chances of severe side effects and a new treatment regimen for increased effectiveness.
This is also a welcome change for the EU/EEA countries struggling to successfully treat drug-resistant patients. In 2017, only 45% of patients with MDR-TB were treated successfully and for extensively drug-resistant TB (XDR-TB), the more resistant form of the disease, only 28% were reported as successfully treated.
Timely diagnostic tests are vital
Proper and fast diagnosis of TB is essential. The sooner a patient is diagnosed, the faster their treatment can begin, easing suffering and preventing further disease transmission. The new report indicates that just over half of all newly notified TB patients were tested using WHO-recommended rapid diagnostic tests. To improve diagnoses and ensure appropriate treatment approaches, it is also important to have capacity at country level to rapidly detect drug-resistant TB.
Overall, the situation in the European Region is improving too slowly to end TB by 2030. In order to reach the SDG target on TB, new intersectoral approaches are required, current tools need to be used more effectively and a people-centered approach to care is paramount.
Source: Eurekalert
Extra Pulmonary Tuberculosis
Extra pulmonary tuberculosis is infection of tissues and organs other than the lungs by mycobacterium tuberculosis and related organisms.
Advertisement
"TB is preventable and curable; the time to take action is now to end TB by 2030. If we don't act rapidly and decisively, the drug-resistant forms of the disease will increase their hold on Europe. Despite the challenges and threats that we face, I believe that Europe has the full potential to lead the way. We have science and technology, skilled health professionals and high level political commitment to leaving no-one behind - we have got what it takes to end TB", said Dr Zsuzsanna Jakab, WHO Regional Director for Europe.
The recent United Nations High-Level Meeting on TB, held in September 2018, brought hope to the world as global leaders stepped up their commitment to end TB by 2030, in line with the Sustainable Development Goals (SDGs). This political commitment now needs to be translated into action to end TB.
New hope for treatment of drug-resistant TB
Up until now, an MDR-TB diagnosis spelled the start of a grueling two-year treatment plan for patients. New WHO recommendations for the treatment of MDR-TB involve safer and more effective drugs with reduced chances of severe side effects and a new treatment regimen for increased effectiveness.
This is also a welcome change for the EU/EEA countries struggling to successfully treat drug-resistant patients. In 2017, only 45% of patients with MDR-TB were treated successfully and for extensively drug-resistant TB (XDR-TB), the more resistant form of the disease, only 28% were reported as successfully treated.
Timely diagnostic tests are vital
Proper and fast diagnosis of TB is essential. The sooner a patient is diagnosed, the faster their treatment can begin, easing suffering and preventing further disease transmission. The new report indicates that just over half of all newly notified TB patients were tested using WHO-recommended rapid diagnostic tests. To improve diagnoses and ensure appropriate treatment approaches, it is also important to have capacity at country level to rapidly detect drug-resistant TB.
Overall, the situation in the European Region is improving too slowly to end TB by 2030. In order to reach the SDG target on TB, new intersectoral approaches are required, current tools need to be used more effectively and a people-centered approach to care is paramount.
Source: Eurekalert
Screening Tests for Tuberculosis
Tuberculin skin test and Interferon - Release Assays are tests used to screen for tuberculosis.
Advertisement
 TuberculosisTuberculosis, caused by Mycobacterium tuberculosis, primarily affects the lung. It may spread to other organs. | Advertisement
|
Advertisement
Recommended Readings
Latest Respiratory Disease News
C-PAP-Continuous positive airway pressure used to treat loud snoring, can also diminish heartburn and respiratory complaints.
Imaging has the potential to assist in identifying the appropriate antibiotics for treating different lung infections, including pneumonia and cystic fibrosis
New study compared the effect of different types of exercise in improving lung function in adult patients with asthma using Network Meta-analysis.
Adenovirus infection is tied to severe blood clotting disorders like thrombocytopenia, a new study reveals.
Can food allergy affect lung health? Infants with food allergy are at higher risk of developing asthma later in childhood.
